Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening | Contract Pharma
Sponsored Content

Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening

Drug formulation is one of the most critical aspects of the product life cycle from early clinical trials to commercial product launch.

Released By Bora Biologics

Formulation development for biologic drugs is the process of determining the best way to deliver stable active ingredients to the intended patient population. Drug formulation is one of the most critical aspects of the product life cycle from early clinical trials to commercial product launch. The selected inactive ingredients, or excipients, must ensure stability of the biologic drug under a variety of conditions, including shipment and storage. To achieve a successful formulation, critical decisions that depend upon a range of biochemical and physical attributes of the drug substance must be made early in the development process. As a result, extensive characterization of the biomolecule and the physicochemical properties of the drug product are necessary to understand the potential impact of various excipients on stability and critical quality attributes. Tanvex CDMO has developed unique biophysical and analytical screening platforms that are faster and more accurate and cost-effective than traditional approaches to biopharmaceutical formulation development.

Fill out the form to download the article >>>

Download Sponsored Content Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters